Vox Sanguinis International Forum on typing and matching strategies in patients on anti‐CD38 monoclonal therapy: summary.

The article reports that the immunotherapeutic strategies are emerging as novel therapeutic approaches in multiple myeloma with several monoclonal antibodies being in advanced stages of clinical development. CD38 targeting antibodies are promising and some of them are in the market in many countries. Therapeutic CD38-targeting antibodies were shown to interfere with pretransfusion laboratory tests due to weak expression of CD38 on human erythrocytes.